Cargando…

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis

OBJECTIVE: This study aimed to explore the prognostic value of the lymphocyte (LYM)-to-white blood cell (WBC) ratio (LWR) in patients with decompensated liver cirrhosis (DLC). METHODS: This study was conducted by recruiting 214 patients with DLC with different aetiologies (development cohort). Recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yanan, He, Chiyi, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662056/
https://www.ncbi.nlm.nih.gov/pubmed/36369931
http://dx.doi.org/10.1080/07853890.2022.2142277
_version_ 1784830609749704704
author Xie, Yanan
He, Chiyi
Wang, Wei
author_facet Xie, Yanan
He, Chiyi
Wang, Wei
author_sort Xie, Yanan
collection PubMed
description OBJECTIVE: This study aimed to explore the prognostic value of the lymphocyte (LYM)-to-white blood cell (WBC) ratio (LWR) in patients with decompensated liver cirrhosis (DLC). METHODS: This study was conducted by recruiting 214 patients with DLC with different aetiologies (development cohort). Receiver operating characteristic (ROC) curve analyses were used to assess the predictive accuracy of the LWR, and Youden’s index was used to determine the optimal cut-off values of the LWR based on the ROC curve. Next, patients were divided into high- and low-LWR groups according to the cut-off values. Multivariate logistic analyses were performed to determine the independent predictors for the 1-, 3- and 6-month mortality. Restricted cubic spline (RCS) was used to determine and visualize the association between LWR and the risk of death. We verified the predictive ability of LWR in the validation cohort of 139 patients. RESULTS: In the development cohort, there were 16 (7.5%), 22 (10.3%) and 30 patients (14.0%) who died at 1, 3 and 6 months, respectively. The LWR was significantly lower in non-survivors than in survivors and was an independent predictor of poor outcomes. The ROC analyses with the Delong test showed that the LWR had comparable predictive power with the Model for End-Stage Liver Disease (MELD) score, neutrophil-to-LYM ratio (NLR) and Chronic Liver Failure consortium score for acute decompensated (CLIF-C ADs). RCS showed a non-linear relationship between the LWR and the risk of death at 1 and 3 months, whereas a linear relationship was observed between the LWR and the risk of death at 6 months. We verified that the decreased LWR was an independent predictor of adverse outcomes at 3-, and 6-month follow-up endpoints in the validation cohort. CONCLUSIONS: Our findings indicate that a lower LWR is an independent factor for unfavourable outcomes and may serve as a potential novel prognostic predictor in patients with DLC. KEY MESSAGES: This study is the first report on the prognostic value of the lymphocyte (LYM)-to-white blood cell (WBC) ratio (LWR) in patients with decompensated liver cirrhosis (DLC). Decreased LWR is an independent factor for adverse outcomes in patients with DLC.
format Online
Article
Text
id pubmed-9662056
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-96620562022-11-15 A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis Xie, Yanan He, Chiyi Wang, Wei Ann Med Gastroenterology & Hepatology OBJECTIVE: This study aimed to explore the prognostic value of the lymphocyte (LYM)-to-white blood cell (WBC) ratio (LWR) in patients with decompensated liver cirrhosis (DLC). METHODS: This study was conducted by recruiting 214 patients with DLC with different aetiologies (development cohort). Receiver operating characteristic (ROC) curve analyses were used to assess the predictive accuracy of the LWR, and Youden’s index was used to determine the optimal cut-off values of the LWR based on the ROC curve. Next, patients were divided into high- and low-LWR groups according to the cut-off values. Multivariate logistic analyses were performed to determine the independent predictors for the 1-, 3- and 6-month mortality. Restricted cubic spline (RCS) was used to determine and visualize the association between LWR and the risk of death. We verified the predictive ability of LWR in the validation cohort of 139 patients. RESULTS: In the development cohort, there were 16 (7.5%), 22 (10.3%) and 30 patients (14.0%) who died at 1, 3 and 6 months, respectively. The LWR was significantly lower in non-survivors than in survivors and was an independent predictor of poor outcomes. The ROC analyses with the Delong test showed that the LWR had comparable predictive power with the Model for End-Stage Liver Disease (MELD) score, neutrophil-to-LYM ratio (NLR) and Chronic Liver Failure consortium score for acute decompensated (CLIF-C ADs). RCS showed a non-linear relationship between the LWR and the risk of death at 1 and 3 months, whereas a linear relationship was observed between the LWR and the risk of death at 6 months. We verified that the decreased LWR was an independent predictor of adverse outcomes at 3-, and 6-month follow-up endpoints in the validation cohort. CONCLUSIONS: Our findings indicate that a lower LWR is an independent factor for unfavourable outcomes and may serve as a potential novel prognostic predictor in patients with DLC. KEY MESSAGES: This study is the first report on the prognostic value of the lymphocyte (LYM)-to-white blood cell (WBC) ratio (LWR) in patients with decompensated liver cirrhosis (DLC). Decreased LWR is an independent factor for adverse outcomes in patients with DLC. Taylor & Francis 2022-11-12 /pmc/articles/PMC9662056/ /pubmed/36369931 http://dx.doi.org/10.1080/07853890.2022.2142277 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Gastroenterology & Hepatology
Xie, Yanan
He, Chiyi
Wang, Wei
A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
title A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
title_full A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
title_fullStr A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
title_full_unstemmed A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
title_short A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
title_sort potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
topic Gastroenterology & Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662056/
https://www.ncbi.nlm.nih.gov/pubmed/36369931
http://dx.doi.org/10.1080/07853890.2022.2142277
work_keys_str_mv AT xieyanan apotentialnovelinflammationbiomarkerforpredictingtheprognosisofdecompensatedlivercirrhosis
AT hechiyi apotentialnovelinflammationbiomarkerforpredictingtheprognosisofdecompensatedlivercirrhosis
AT wangwei apotentialnovelinflammationbiomarkerforpredictingtheprognosisofdecompensatedlivercirrhosis
AT xieyanan potentialnovelinflammationbiomarkerforpredictingtheprognosisofdecompensatedlivercirrhosis
AT hechiyi potentialnovelinflammationbiomarkerforpredictingtheprognosisofdecompensatedlivercirrhosis
AT wangwei potentialnovelinflammationbiomarkerforpredictingtheprognosisofdecompensatedlivercirrhosis